![](https://ias-education.athero.org/wp-content/uploads/2020/07/Jennifer-Robinson@2x.png)
Jennifer G. Robinson
MD, MPH
PROFESSOR DEPARTMENT OF EPIDEMIOLOGY & MEDICINE DIRECTOR
Prevention Intervention Center Department of Epidemiology University of Iowa Iowa City, IA, USA
Jennifer G. Robinson, MD, MPH is a Professor in the Departments of Epidemiology and Medicine (Division of Cardiology), and Director of the Prevention Intervention Center at the University of Iowa, Iowa City, Iowa.
As an active researcher, Dr. Robinson has performed numerous clinical trials sponsored by the National Institutes of Health and the pharmaceutical industry. She has conducted extensive research on a wide range anti-atherosclerotic and metabolic agent, including lipid-modifying, anti-inflammatory, antihypertensive, weight loss, and diabetic treatments as well as postmenopausal hormone therapy. She is the principal investigator for the Women’s Health Initiative (WHI) at the University of Iowa. Her current research interests include clinical trials to cure atherosclerosis.
Dr. Robinson has published over 250 peer-reviewed publications in the areas of lipids-modifying drugs, cardiovascular risk stratification, and cardiovascular prevention, with multiple recent publications in the New England Journal of Medicine, JAMA, Journal of the American College of Cardiology and Circulation. She has lectured widely on preventive cardiology and the diagnosis and treatment of disorders of lipid metabolism in the US and internationally.
She was Vice Chair of the 2013 ACC/AHA cholesterol guideline, and a member of the 2013 ACC/AHA risk assessment guideline. In addition to long involvement in multiple American Heart Association (AHA) committees, recent leadership roles include serving as Chair of the Lifestyle Track for the American Heart Association Scientific Sessions. She was the 2017 Chair of the National Forum for Heart Attack and Stroke Prevention, a consortia of over 90 governmental, public health, academic, and industry groups.
While at the University of Minnesota in Minneapolis, Dr. Robinson received her medical degree and completed an Internal Medicine residency with the College of Medicine and received a Master of Public Health from the College of Public Health. She is a diplomate of the American Boards of Internal Medicine and Clinical Lipidology and a Fellow of the American Heart Association.
DISCLOSURES: Research grants to Institution: Acasti, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Medicines Company, Merck, Novartis, Novo-Nordisk, Regeneron, Sanofi.
Consultant: COR2ED, Novartis.